AMGN Amgen, Inc.

All AMGN filings Filing statistics SEC Website

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Company profile

Ticker

AMGN

Exchange

NASDAQ

CEO

Robert A. Bradway

Incorporated in

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Health Technology > Biotechnology

Industry (SEC)

Biological Products, (No Diagnostic Substances)

Gilead Sciences • Biogen • Qiagen • Acorda Therapeutics • PDL BioPharma • BioNTech SE • Denali Therapeutics • Seattle Genetics • Vir Biotechnology • China Biologic Products ...

Former names

AMGEN

SEC CIK

0000318154

Corporate docs

Articles of Incorporation & Bylaws

Subsidiary Companies

IRS number

953540776

AMGN stock data

S&P 500

1M 1Y 2Y 5Y

Company financial data Financial data

Chart AMGN financial data

Download latest Excel data (2019 Q2) View latest Excel data (2019 Q2)

Quarter (USD)	Jun 19	Mar 19	Dec 18	Sep 18
Revenue	5.87B	5.56B	6.23B	5.9B
Net income	2.18B	1.99B	1.93B	1.86B
Diluted EPS	3.57	3.18	3.01	2.86
Net profit margin	37.11%	35.85%	30.95%	31.49%
Operating income	2.68B	2.47B	2.38B	2.32B
Net change in cash	-8M	69M	77M	-56M
Cash on hand	641M	649M	580M	503M
Cost of revenue	1.01B	1.06B	1.1B	1.04B

Annual (USD)	Dec 18	Dec 17	Dec 16	Dec 15
Revenue	23.75B	22.85B	22.99B	21.66B
Net income	8.39B	1.98B	7.72B	6.94B
Diluted EPS	12.62	2.69	10.24	9.06
Net profit margin	35.35%	8.66%	33.59%	32.03%
Operating income	10.26B	9.97B	9.79B	8.47B
Net change in cash	71M	51M	52M	-32M
Cash on hand	580M	509M	458M	406M
Cost of revenue	4.1B	4.07B	4.16B	4.23B

Financial data from Amgen earnings reports

Financial report summary

Competition

Scio Diamond Technology • Poniard Pharmaceuticals • Imclone Systems • Ir Biosciences • Celgene • ImmunoCellular Therapeutics • Novelion Therapeutics • Spectrum Pharmaceuticals • Medimmune • Genaera

Management Discussion

Future sales of our products will depend in part on the factors discussed below and in the following sections of our Annual Report on Form 10-K for the year ended December 31, 2018: (i) Item 1. Business—Marketing, Distribution and Selected Marketed Products, (ii) Item 1A. Risk Factors and (iii) Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Overview, and Results of Operations—Product Sales, as well as in our Quarterly Report on Form 10-Q for the period ended March 31, 2019, in (i) Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Results of Operations—Product Sales; and (ii) Part II, Item 1A. Risk Factors.

Content analysis ?

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: adjuvant, agriculture, Allergan, Alzheimer, AML, amyloid, analytical, avoid, await, BACE, Bankruptcy, belonging, BioPharma, Blue, breakdown, calcimimetic, certified, chain, chair, Chapter, CHMP, civil, clause, Cleveland, Code, coinsurance, compromise, Congressional, Constitution, constitutional, crime, cyberattack, debtholder, deferral, demographic, deposit, destroyed, detailed, detect, Deutschland, diesel, disaster, disconnect, discretionary, dispensed, dissipate, draft, DRL, dynamic, economy, EMA, embedded, engineering, environment, evidentiary, experienced, facilitate, familial, frequency, fully, gastric, governmental, governor, grid, harm, harmful, HHS, HMO, hold, home, hosted, House, hypercholesterolemia, inadvertent, incentivizing, Indemnity, infirmity, infrastructure, inhibitor, inline, instability, insufficient, interactive, interconnected, IPI, jeopardy, kidney, landfall, landscape, leave, leaving, legislature, lone, Louisiana, mainland, malware, mandatory, Maria, migration, monitoring, moratorium, multinational, opposition, Oregon, organized, outage, oversight, owed, panel, penalize, personal, political, PRALUENT, preliminarily, PREPA, presidential, privacy, PROMESA, purposed, ransomware, raw, rebate, reconnect, reconnected, reconstruction, recover, reexamination, refuse, reimportation, reliably, renal, residential, resilience, restoration, restraining, Rican, rollout, roughly, Sagent, sector, sensitive, Shield, situation, smaller, smooth, social, sophisticated, sophistication, sponte, stability, store, storm, sua, sued, suit, sustain, Tanvex, threshold, Title, transmit, transported, twelve, unauthorized, unavailability, unconstitutional, uninterrupted, unrest, unsuccessful, vendor, virulent, volume, vulnerable, waited, Western, withdraw, withdrawal

Removed: begun, commercialization, consist, develop, infringed, initiated, interpretation, Italy, Jersey, Kingdom, lengthen, lesser, making, migraine, myelosuppressive, offering, pegfilgrastim, requirement, reverse, shorten, site, Spain, stipulation, supplementary, validity

From filing 10-Q 2019 Q2